ARTICLE | Company News

NICE backs Victoza for Type II diabetes

September 10, 2010 1:09 AM UTC

The U.K.'s NICE issued a final appraisal determination for Victoza liraglutide from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) to treat Type II diabetes. NICE recommended the 1.2 mg dose of Victoza in triple therapy regimens (in combination with metformin and a sulfonylurea, or metformin and a thiazolidinedione). The committee also recommended Victoza as dual therapy (in combination with metformin or a sulfonylurea) if the person is intolerant to either metformin or a sulphonylurea, or treatment with either is contraindicated and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with the combination is contraindicated. The FAD is in line with a June preliminary appraisal. ...